{"nctId":"NCT00447499","briefTitle":"Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel","startDateStruct":{"date":"2007-04"},"conditions":["Acromegaly"],"count":59,"armGroups":[{"label":"Somatuline Autogel (lanreotide acetate)","type":"EXPERIMENTAL","interventionNames":["Drug: Somatuline Autogel (lanreotide acetate)","Behavioral: Home administration"]}],"interventions":[{"name":"Somatuline Autogel (lanreotide acetate)","otherNames":[]},{"name":"Home administration","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* The subject must give signed informed consent before any study-related activities.\n* The partner, if applicable, must give signed informed consent before administration of Somatuline Autogel.\n* The subject must be able to understand the protocol requirements.\n* The subject must have a clinical diagnosis of acromegaly due to pituitary tumor.\n* The subject must be treated with a long-acting somatostatin analogue with or without a dopamine agonist and have been on the current medical regimen for at least 3 months prior to screening and have IGF-1 levels no higher than 10% above the upper limit of the normal range for age and gender at the screening visit or be somatostatin analogue naïve (if the subject is treated with a dopamine agonist he/she must have been on the current dose for at least 3 months prior to screening).\n* Subjects who are treated with a dopamine agonist have to stay on their current dose for the duration of the study.\n* Switch subjects must have had their last pre-study routine clinical treatment with Sandostatin LAR between 28 and 35 days before Visit 2 (enrollment).\n* The subject must be able to store the study medication in a refrigerator in his/her own or his/her partner's home.\n* The subject must be ≥18 years of age.\n* Female subjects of childbearing potential must use adequate contraception.\n* Female subjects of childbearing potential who are taking oral contraceptives must agree to stay on their current contraceptive dose for the duration of the study.\n* The partner, if applicable, must be ≥18 years of age.\n\nExclusion Criteria:\n\n* The subject has had pituitary surgery (adenomectomy) within 3 months prior to screening.\n* The subject has received pituitary radiotherapy within 3 years prior to screening.\n* The subject has received a GH receptor antagonist within 6 months prior to screening.\n* The subject is currently on a higher dose of Sandostatin LAR than 30mg q28d\n* The subject is pregnant or breastfeeding.\n* The subject has clinically significant renal or hepatic abnormalities.\n* The subject has a symptomatic, untreated biliary lithiasis.\n* The subject has uncontrolled diabetes or thyroid disease.\n* The subject has a known hypersensitivity to any of the test materials or related compounds.\n* The subject is unable or unwilling to comply with the protocol.\n* The subject has received any investigational drug within 30 days prior to screening.\n* The subject has participated in a medical device study within 30 days prior to screening.\n* The subject has previously participated in this study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"The Percentage of Subjects or Their Partners That Are Competent to Self-administer Somatuline Autogel at the End of the Study, (Week 24/Early Termination), as Assessed by the Competence Questionnaire Score.","description":"The primary efficacy endpoint was the percentage of patients (Switch and other) or their partners who were competent to self-administer lanreotide at the end of the study (Week 24/Early Termination), as assessed by the Assessment of Competence Questionnaire (0 = 'No' and 1 = 'Yes').","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Switch Subjects Who Find Self-administration of Somatuline Autogel Convenient as Assessed by the Subject Convenience Questionnaire Score.","description":"Experienced Convenience of Somatuline® Autogel® Injections was assessed by the subject as: Very convenient; somewhat convenient; neither convenient nor inconvenient; Neither convenient nor inconvenient; Somewhat inconvenient; very inconvenient.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"91","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Switch Subjects That Have IGF-1 Levels Within the Normal Range for Age and Gender at the End of the Study","description":"Blood sample was collected while subject is in a fasting state or non-fasting state for measuring the level of IGF-1.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"94","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Switch Subjects That Have Glucose Suppressed GH Levels ≤ 2.5 ng/ml at the End of the Study, Week 24/Termination.","description":"Blood samples taken before and 60 and 120 min after glucose load from fasting patient.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null}]}]}]},{"type":"SECONDARY","title":"Change of GH Concentration Levels From Basaeline to Week 24 in Switch Patients","description":"Blood samples taken before and 60 and 120 min after glucose load from fasting patient.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.3","spread":"1.3"}]}]}]},{"type":"SECONDARY","title":"Total Symptom Questionnaire Score at Week 24/Termination","description":"Acromegaly symptoms are sweating, snoring, joint pain, headache and fatigue. Each symptom was scored as -2 = 'always', -1 = 'most of the time', 0 = 'sometimes', 1 = 'rarely and 2 = 'never'. The total score was used to evaluate symptom control in each patient at Week 0 and Week 24/Termination. The total worst score is -10 and best score is 10.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":"3.6"}]}]}]},{"type":"SECONDARY","title":"Total Health Care Professional Convenience Questionnaire Score at Week 24/Termination","description":"Healthcare professional convenience questionnaires are: Confident the Subject Properly Administering the Injection; Subject Complained About Pain When Administering the Injection; Subject Appreciated the Option of Self-Injection at Home. Each Healthcare professional convenience questionnaire was scored -2, -1, 0, 1 and 2; from most negative to most positive response. A total score across all questions was calculated and was used to evaluate the convenience. The worst total score is -6 and best total score is 6.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.6","spread":"1.8"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":59},"commonTop":["Diarrhoea","Headache","Injection Site Pain","Nausea","Abdominal Pain"]}}}